Establishment and validation of corrected SUVmax correlated with prognosis following stereotactic body radiotherapy for non-small cell lung cancer

非小细胞肺癌立体定向放疗后校正SUVmax与预后相关的建立和验证

• 批准号: 23591850
• 负责人: TAKEDA Atsuya
• 金额: $ 3.16万
• 依托单位: Tokai University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2011
• 资助国家: 日本
• 起止时间: 2011 至 2013
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23591850/
• 关键词: 体幹部定位放射線治療; 非小細胞肺癌; FDG-PET; SUVmax; 予後因子; 定位放射線治療

SUVmax is an index of accumulation in FDG-PET, and is expected to be a prognostic factor of various cancer. However, it is a relative index and is affected by tumor size, respiratory movement, tumor background, instrument and so on. We made an experiment using moving phantom and tried to correct SUVmax modified with tumor size and respiratory movement. Next, availability of the corrected SUVmax was investigated on the treatment results data of stereotactic body radiotherapy for patients with non-small cell cancer.As results, actual SUVmax and corrected SUVmax were correlated well with local control and disease-free control. However, corrected SUVmax was not shown to be more correlated with those outcomes.

SUVmax是FDG-PET中的累积指标，并且预期是各种癌症的预后因子。但SUVmax是一个相对的指标，受肿瘤大小、呼吸运动、肿瘤背景、仪器等因素的影响，我们利用运动体模进行了实验，尝试用肿瘤大小和呼吸运动修正SUVmax。其次，根据非小细胞癌患者立体定向体部放疗的治疗结果数据，研究了校正后的SUVmax的可用性，结果显示，实际SUVmax和校正后的SUVmax与局部控制和无病控制相关性良好。然而，校正的SUVmax与这些结果的相关性并不高。